AI-generated · cited to primary sources · not investment advice
Dr Agarwal's Hea (544350) Jun 2025 Filing Analysis
Does management do what it says?
Management intends to selectively relocate mature facilities to cater to high demand areas.
“Selective relocation of mature facilities to cater to high demand”
See the full cited Management analysis of Dr Agarwal's Hea
How durable is the business?
Surgical revenues remain the dominant pillar, with volumes growing 28% year-on-year for the full year. High-end cataract surgeries increased their contribution to the mix.
“in FY '25, the surgical revenues form the main pillar of our service offering, contributing to”
The company is aggressively expanding its footprint, adding 59 facilities in FY25 and targeting another 55-60 in FY26, with a focus on the southern states and Maharashtra.
“Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities”
Adoption of high-end technology is accelerating, specifically in laser cataract (Femto) and refractive surgery (SMILE), which is driving premiumization.
“increase in contribution coming in from high-end cataract surgeries, which has moved up from 19”
The revenue contribution from India has increased as the company focuses on domestic expansion, particularly in Tier 2 and Tier 3 cities.
“There has been greater focus on India, with its contribution to the overall group revenue increasing from 87.2% in FY '24 to 89.9% in FY '25. Revenue from operations in India for FY '25 totaled INR1538 crores, marking a growth of 32.3% year-on-year”
Revenue from opticals and pharmaceuticals grew 27.5% but its share of the total revenue mix remained stable at approximately 20.8%.
“Opticals, Contact Lens, and Accessories & Pharmaceutical Products 20.8%”
See the full cited Business Model analysis of Dr Agarwal's Hea
Where does growth come from?
The adoption of high-end laser-assisted (Femto) cataract surgeries is accelerating, with contribution to total cataract volume rising from 19.2% in FY24 to 22.5% in FY25.
“increase in contribution coming in from high-end cataract surgeries, which has moved up from 19.2% in FY '24 to 22.5% in FY '25”
Refractive surgery (vision correction) is showing explosive growth, significantly outpacing the core cataract segment.
“We have also seen an uptick in the refractive surgery segment, where we witnessed a 44% overall growth in the number of surgeries, and we have done 15,989 refractive surgeries in the year FY '25”
The geographic expansion is accelerating, particularly in North and West India, moving away from a South-only concentration.
“30.6% CAGR Growth in Total Facilities over FY2022 – FY2025”
Full-year PAT grew 16% to INR 110 crores, but management is projecting a significant acceleration to 35%+ growth for FY26.
“Our profit after tax stood at INR110 crores, reflecting a 16% year-on-year growth”
The company is maintaining a steady, aggressive expansion pace, adding 59 facilities in FY25 and targeting another 55-60 in FY26.
“Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities”
See the full cited Future Growth analysis of Dr Agarwal's Hea
What could break the thesis?
The risk is intensifying as the company plans to accelerate expansion to 55-60 new facilities in FY26 (up from 59 in FY25), with a significant capex of INR 310 crores.
“Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities”
Management expects EBITDA margins to remain stable despite ongoing greenfield investments, but the sheer volume of new openings (55-60) keeps this risk elevated.
“We expect our EBITDA margin to remain stable as ongoing greenfield investments continue to impact profitability”
Manpower costs grew by 28.4% YoY, exactly in line with revenue growth (28.4%), suggesting costs are currently being managed but remain a high-growth expense item.
“Manpower costs for the year totaled INR574 crores, up by 28.4% compared to last year. This was driven by strategic hiring and increase in our workforce due to addition of new facilities”
See the full cited Risk analysis of Dr Agarwal's Hea
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.